Valion Bio Announces Changes to Management and Board of Directors

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors. * Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation Syndrome ("ARS") market by 2032 and a multi-billion-dollar oncology supportive-care opportunity through its differentiated dual-tissue cytoprotection platform¹(˒)² * Focused on Value Creation: Streamlined leadership and additional Board expertise are designed to accelerate execution, strengthen commercial opportunities and better align Valion's market valuation with the underlying value of its assets, capabilities, and future prospects

SAN ANTONIO, TX / ACCESS Newswire / September 1, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for its next phase of growth.